Pharmacology for Nurses · Anti-infective Drugs
Introduction to Tuberculosis and Antitubercular Drugs
On this page 9 sections
In 30 seconds
Tuberculosis (TB) is caused by Mycobacterium tuberculosis Slow-growing bacterium with a waxy cell wall causing TB Full entry →, a slow-growing bacterium with a waxy cell wall that makes it unusually hardy and hard to treat. TB usually attacks the lungs (pulmonary TB) but can spread to almost any organ (extrapulmonary TB). It spreads through the air when a person with active pulmonary TB coughs, sneezes, or speaks — not by shaking hands or sharing dishes.
The single most important concept is the difference between Latent TB infection (LTBI) Bacteria present but dormant; no symptoms, not contagious Full entry → and Active TB disease Multiplying bacteria causing symptoms; contagious. When a person inhales the bacteria, the immune system usually walls them off inside granulomas, where they stay alive but dormant: the person has LTBI — no symptoms, not contagious, but with a positive TB test. Years later, if immunity weakens (HIV, malnutrition, aging, immunosuppressive therapy), the bacteria can reactivate and cause active disease — symptomatic and contagious. Both are treated, with different goals: LTBI treatment prevents future disease; active TB treatment cures and stops transmission.
Antitubercular drugs are grouped into first-line agents (standard regimens) and second-line agents (for resistance or intolerance). Because M. tuberculosis grows slowly and readily develops resistance, TB is never treated with a single drug — standard therapy uses multiple drugs in combination for months.
Why this matters
TB remains one of the world's deadliest infectious diseases, and drug-resistant TB is a growing threat. For nurses: infection control — recognizing who needs airborne precautions (negative-pressure room, respirator, masking the patient) protects everyone; case finding — TB is reportable and nurses participate in contact tracing; adherence is the treatment — regimens last months, people feel better before cured, and stopping early breeds resistance, which is why Directly observed therapy (DOT) A health worker watches each dose being taken Full entry → is a cornerstone; monitoring is safety — first-line drugs can affect the liver. On exams, the latent-vs-active distinction and the "always combination therapy" rule are classic high-yield items.
The college version
Core Concepts
Latent vs. active TB: the two clinical states
Latent TB infection — bacteria present but contained; the person feels well and cannot transmit disease. Diagnosis is by positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA). Treatment reduces the lifetime risk of reactivation, especially in people at high risk (recent exposure, HIV, immunosuppression).
Active TB disease — bacteria multiplying and causing symptoms: persistent cough (sometimes with blood), night sweats, fever, weight loss, fatigue. Diagnosis typically involves symptoms plus chest imaging and sputum testing (smear, culture, molecular tests). The person is contagious until treatment has been underway long enough per current guidelines; the multi-drug regimen, phases, and duration also follow current guidelines.
Why TB treatment is long and combination-based
M. tuberculosis divides roughly once a day — far slower than typical bacteria — so therapy must last months to catch every generation as it becomes active. Its waxy cell wall resists many common antibiotics, and bacteria can survive dormant for decades. Combination therapy makes it nearly impossible to develop resistance to all drugs at once — monotherapy selects resistant strains.
First-line antitubercular drugs (classes and mechanisms)
- Rifamycins (e.g., rifampin) inhibit bacterial RNA polymerase, blocking transcription. They are a TB backbone and potent enzyme inducers — they speed up the liver's metabolism of many other drugs (oral contraceptives, warfarin, some antiretrovirals), causing important interactions. They also color body fluids orange-red — expected and harmless.
- Isoniazid Drug blocking mycolic acid synthesis (cell wall) Full entry → inhibits mycolic acid synthesis, unique to mycobacteria. Monitor for hepatotoxicity and peripheral neuropathy; vitamin B6 (pyridoxine) is co-administered per the regimen.
- Pyrazinamide works in the acidic environment inside macrophages where bacteria hide; most active early in treatment.
- Ethambutol inhibits another cell-wall component (arabinogalactan). Monitor for optic neuritis — changes in color vision or acuity.
These four are the classic "RIPE" backbone. Specific drugs, doses, durations, and phases follow current guidelines, susceptibility results, and individual factors — always verify against current references and prescriber orders.
Second-line agents and drug-resistant TB
Resistance to first-line drugs defines multidrug-resistant TB (MDR-TB) — at least isoniazid and rifampin — and extensively drug-resistant TB (XDR-TB) adds more classes. Treatment shifts to second-line agents (fluoroquinolones, aminoglycosides, others) in regimens that are longer, more toxic, and costlier. Every incomplete regimen is how resistance is born.
Directly observed therapy and adherence
Because the stakes of nonadherence are so high, TB programs often use DOT — a trained person watches the patient take each dose, in person or via video per program design. Nurses manage scheduling and side effects so the person doesn't stop, and teach that "you will feel better in weeks, but you must finish months of therapy."
Common Confusions
| Do Not Confuse | With | Difference |
|---|---|---|
| Latent TB | Active TB | Latent = dormant, asymptomatic, not contagious; active = multiplying, symptomatic, contagious |
| Positive TST/IGRA | Active TB disease | A positive test only shows exposure; latent vs. active needs symptoms, imaging, and sputum testing |
| TB precautions | Contact precautions | TB spreads by air — airborne precautions, not contact isolation |
| Rifampin orange urine | Bleeding or adverse reaction | Orange-red body fluids are a harmless, expected effect — teach it so it isn't mistaken for blood |
| One drug at a time | Combination therapy | TB requires multiple simultaneous drugs; a single drug guarantees resistance |
| "Feeling better = cured" | Completed regimen | People improve in weeks but need months of therapy; stopping early breeds resistance |
| First-line failure = patient failure | Drug resistance | Failure may mean resistant organisms — susceptibility testing guides next steps |
Eli explains
The same idea, in plain words
Explain it like I’m 10
TB germs are like seeds that can stay asleep in your body for years. If your defenses get weak, the seeds wake up and grow, making you cough and feel sick. The medicine is a long-term weed-killing plan: spray for many months, with several different sprays at once, so the weeds can't learn to survive. Stop early, and the toughest weeds come back harder to kill.
Worked example
A nurse in an outpatient clinic sees a person with a six-week cough, night sweats, weight loss, and recent arrival from a region with high TB rates. The nurse's first thought is airborne precautions: the person is masked and placed in a private room, because until proven otherwise, this cough is an airborne hazard. Testing includes chest imaging, sputum smear, culture, and molecular testing, plus TST/IGRA screening of household contacts. The results confirm active pulmonary TB, and the person starts a standard first-line multi-drug regimen per current guidelines, with baseline liver tests and an eye assessment (because of ethambutol). The public health department is notified and contact tracing begins. The nurse teaches: airborne precautions at home until cleared, how to cover coughs, that orange urine from rifampin is expected, and that the pills must be taken daily for the full course even when feeling better, with a DOT worker watching doses. Six months later, sputum cultures are negative and the person is cured — the result of the nurse's quiet, systematic work.
Key takeaways
- Latent ≠ active: LTBI is dormant, asymptomatic, not contagious — treated to prevent reactivation; active TB is symptomatic, contagious — treated to cure and stop spread.
- Transmission is airborne — airborne, not contact, precautions.
- TB is never treated with one drug: combination therapy prevents resistance.
- The RIPE backbone: rifampin, isoniazid, pyrazinamide, ethambutol — each blocks a different bacterial process.
- Treatment lasts months, not days — the bacterium grows slowly and hides dormant.
- Rifampin causes drug interactions and orange-red fluids.
- Monitor key toxicities: isoniazid — liver and neuropathy (pyridoxine per regimen); ethambutol — vision.
- Adherence is the treatment: DOT prevents resistance and failure.
- MDR/XDR-TB requires longer, harder second-line regimens — completion of first-line therapy prevents it.
Check yourself
6 review questions from the chapter. Try each one, then open the answer.
What is the difference between latent TB infection and active TB disease — clinically, in contagiousness, and in treatment goals?
Show answer
LTBI: bacteria dormant in granulomas; the person is well and not contagious; treatment prevents future reactivation. Active TB: bacteria multiplying and causing symptoms; contagious via airborne droplets; treatment cures and stops transmission.
Why must TB be treated with multiple drugs for many months?
Show answer
M. tuberculosis grows slowly and hides dormant in cells, so therapy must continue long enough to kill every generation as it becomes active. Several drugs at once make resistance nearly impossible; monotherapy selects resistant strains.
Name the four classic first-line drugs (the "RIPE" backbone) and a key feature of each.
Show answer
Rifampin (blocks RNA transcription; enzyme inducer), isoniazid (blocks mycolic acid synthesis; monitor liver and nerves), pyrazinamide (active in acidic intracellular environments), ethambutol (blocks cell-wall synthesis; monitor vision). Regimens follow current guidelines.
Why is rifampin famous for drug interactions, and what harmless effect should patients be warned about?
Show answer
Rifampin induces liver enzymes, speeding up metabolism of other drugs (oral contraceptives, warfarin, some antiretrovirals) and reducing their effectiveness. It also turns urine, sweat, and tears orange-red — expected and harmless.
What is directly observed therapy (DOT), and what problem does it solve?
Show answer
DOT means a trained person watches the patient take each dose. It solves the adherence problem: regimens last months, people feel better before cured, and missed doses breed resistance.
Why do isoniazid and ethambutol require specific monitoring?
Show answer
Isoniazid can cause hepatotoxicity and peripheral neuropathy (pyridoxine is co-administered per regimen); ethambutol can cause optic neuritis. Patients report dark urine, jaundice, nausea, numbness/tingling, or vision changes.
Study tools & related lessonsKey vocabulary · Related
Key vocabulary
- *Mycobacterium tuberculosis*
- Slow-growing bacterium with a waxy cell wall causing TB
- Latent TB infection (LTBI)
- Bacteria present but dormant; no symptoms, not contagious
- Active TB disease
- Multiplying bacteria causing symptoms; contagious
- Granuloma
- Wall of immune cells containing dormant TB bacteria
- TST / IGRA
- Tests for immune memory of TB exposure
- Directly observed therapy (DOT)
- A health worker watches each dose being taken
- Rifamycin
- Drug class blocking RNA transcription; enzyme inducer
- Isoniazid
- Drug blocking mycolic acid synthesis (cell wall)
- MDR-TB / XDR-TB
- TB resistant to first-line drugs (MDR) and more classes (XDR)
- Mycobacterium tuberculosis
- Slow-growing bacterium with a waxy cell wall causing TB
Sources & references
This lesson was adapted from the open educational references above; their licenses and attributions are preserved. See Copyright & Licensing.
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.